CG-T1

CG-T1
Product Description

Peptide-Based Topical Therapeutic for Dry Eye Disease (DED)

Product Overview: A Restorative Approach to Dry Eye Disease

CG-T1 is a next-generation peptide-based topical therapy for dry eye disease, advancing toward Phase 2 clinical development in the United States following successful completion of preclinical safety studies.

It targets PAC1R-mediated pathways to restore tear secretion and reduce inflammation, offering a differentiated, restorative approach beyond conventional anti-inflammatory treatments.

Read more Show less

Caregen Co.,Ltd.

  • Country/Region:
    Korea, Republic Of
  • Founded:
    2001
  • On CPHI since:
    2016
  • Certificates:
    3
  • Employees:
    100 - 249
Company types
Biopharmaceutical company
Consumer Goods
Distributor/Import Export
Drug delivery device Supplier/Manufacturer
Manufacturer/Innovator
OTC
Other
Primary activities
API Producer
Biopharmaceutical
Cosmeceuticals
Cosmetic Ingredients
Nutraceuticals
OTC
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
View company profile
Categories
more categories Show less
Specifications
  • Details
    Specifications Product
    • Name: CG-T1
    • Product Type: Peptide-Based Topical Therapy
    • Dosage Form: Ophthalmic Eye Drop
    • Mechanism of Action: PAC1 Receptor–Mediated Signaling
    • Development Stage: Preclinical Safety Studies Completed / IND Filing Planned (2026)
    • Administration Route: Topical Ophthalmic Administration
    • Therapeutic Area: Dry Eye Disease (DED) 
     Application Areas
    • Dry Eye Disease (DED)
    • Ocular Surface Disorders
    • Tear Secretion Activation
    • Tear Film Stabilization
    • Mucin Production Enhancement
    • Ocular Inflammation
    • Oxidative Stress
    • Neuro-Secretory Dysfunction
  • Selling Points
    Key Highlights
    • Peptide-based topical therapy with multimodal activity
    • Enhances mucin production and tear film stability
    • Reduces inflammatory cytokines and oxidative stress
    • Potential for faster onset and improved tolerability vs. cyclosporine
    • Robust efficacy demonstrated in preclinical (in vivo) models
    • IND filing planned with the U.S. FDA (target: 2026) 

    Clinical/Preclinical Highlights
    • Robust efficacy demonstrated in both in vitro and in vivo models
    • Significant improvement in clinical dry eye scores in animal models
    • Faster onset of symptom relief compared to control treatments
    • Increased tear break-up time (TBUT), indicating improved tear film stability
More specifications Fewer specifications

Caregen Co.,Ltd.

  • Country/Region:
    Korea, Republic Of
  • Founded:
    2001
  • On CPHI since:
    2016
  • Certificates:
    3
  • Employees:
    100 - 249
Company types
Biopharmaceutical company
Consumer Goods
Distributor/Import Export
Drug delivery device Supplier/Manufacturer
Manufacturer/Innovator
OTC
Other
Primary activities
API Producer
Biopharmaceutical
Cosmeceuticals
Cosmetic Ingredients
Nutraceuticals
OTC
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
View company profile

More Products from Caregen Co.,Ltd. (5)

  • CG-P5

    Product CG-P5

    First-in-Class VEGFR2-Inhibiting Peptide Eye Drop for Wet Age-Related Macular Degeneration

    Product Overview: A New Standard for Non-Invasive Retinal Therapy
    CG-P5 is a first-in-class VEGFR2-inhibiting biomimetic peptide developed as a topical eye drop for the treatment of wet age-related m...
  • Korglutide

    Product Korglutide

    Korglutide is a next-generation oral dual GLP-1R/IGF-1R peptide designed to support safe and muscle-preserving weight loss as a non-injectable nutraceutical alternative.
    Product Overview
    Korglutide is a synthetic dual GLP-1R and IGF-1R agonist peptide developed by Caregen for weight management and ...
  • MyoKi

    Product MyoKi

    MyoKi is an oral anti-myostatin peptide designed to support muscle mass and strength, enabling safe and effective muscle health management across all age groups.

    Product OverviewMyoKi is a peptide-based nutraceutical developed to support muscle preservation and functional performance t...
  • ProGsterol

    Product ProGsterol

    ProGsterol is an oral peptide-based nutraceutical designed to improve insulin receptor sensitivity and regulate glucose metabolism, supporting overall metabolic balance.
    Product Overview
    ProGsterol is a peptide-based nutraceutical developed by Caregen for metabolic disorders, including insulin re...
  • CG-Luxidase

    Product CG-Luxidase

    CG-Luxidase is a proprietary peptide-based delivery platform designed to enhance the penetration and distribution of active compounds by transiently modulating the hyaluronic acid (HA) network within the extracellular matrix (ECM).

    As a water-soluble synthetic decapeptide (INCI: Decapeptide-51),...

Caregen Co.,Ltd. resources (1)